All In Biotech

Drug Trial Radar · NCT06317805

Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients

Randomized Trial Comparing Efficacy and Safety of Initial Triple Therapy Including Parenteral Treprostinil to Initial Double Oral Therapy in Pulmonary Arterial Hypertension (PAH) Group I Patients (TripleTRE)

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 110 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

110

Planned (sponsor's estimate)

Start

Dec 6, 2023

Primary completion

Jun 2027

Study completion Jun 30, 2027

Sponsor

Lead sponsor
AOP Orphan Pharmaceuticals AGIndustry
Sponsor type
Industry
Collaborators
ANOVA CRO s.r.o.; PharmaLex Belgium; Aixial s.r.o.; GCP-Service International Ltd. & Co. KG
First posted
Mar 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TripleTRE investigates the effect of initial triple combination therapy (oral endothelin receptor antagonist (ERA) + oral phosphodiesterase tyüe-5 inhibitor (PDE-5i) + parenteral treprostinil) compared to double oral therapy (oral ERA + oral PDE-5i) in pulmonary arterial hypertension (PAH) patients (group I) with intermediate-high risk or patients with intermediate-low risk with severe hemodynamic impairment at baseline in a prospective, randomized, unblinded setting with scope of increasing evidence for optimization of therapy concepts in PAH. The effect of initial triple combination therapy vs initial double oral therapy (standard of care (SoC)) will be measured by primary endpoint: (non)response to the assigned treatment.

Conditions

  • Pulmonary Arterial Hypertension

Interventions

  • Generic treprostinil sodium + Standard of Care (Double Oral)Drug

    Treprostinil (prostacyclin analogue) solution for continuous subcutaneous (SC) or intravenous (IV) infusion (1 mg/ml; 2.5 mg/ml; 5 mg/ml; 10 mg/ml in 10 mL glass vial) will be administered by an infusion pump system and up-titrated to ≥40 ng/kg/min or to the maximum tolerated dose within 24 weeks. Further up-titration shall be performed until trial completion according to the discretion of the investigator.

  • Standard of Care - Double OralDrug

    All patients will receive standard of care double oral background treatment consisting of one Phosphodiesterase type 5 inhibitor (i.e., tadalafil or sildenafil) and one Endothelin Receptor Antagonist (i.e. ambrisentan, bosentan or macitentan)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patients achieving (non-)response status to the assigned treatment in terms of achievement of low-risk statusTime frame: between week 12 and week 48 from baseline (BL)

Locations

28 sites in 12 countries. Site status is shown where the registry gives one.

  • Instituto Neumonológico del Sur (INEUS)

    Bahía Blanca, Argentina · Active not recruiting

  • Centro Gallego de Buenos Aires

    Buenos Aires, Argentina · Active not recruiting

  • Fundación Favaloro

    Buenos Aires, Argentina · Active not recruiting

  • Hospital Británico de Buenos Aires

    Buenos Aires, Argentina · Active not recruiting

  • Hospital Italiano de Buenos Aires (HIBA)

    Buenos Aires, Argentina · Active not recruiting

  • Hospital Ramos Mejia

    Buenos Aires, Argentina · Active not recruiting

  • Sanatorio Mitre de Buenos Aires

    Buenos Aires, Argentina · Active not recruiting

  • Centro Médico Capital

    La Plata, Argentina · Active not recruiting

  • Ordensklinikum Linz

    Linz, Austria · Recruiting

  • Medical University Vienna

    Vienna, Austria · Recruiting

  • Fakultní Nemocnice Olomouc

    Olomouc, Czechia · Not yet recruiting

  • Všeobecná fakultní nemocnice v Praze

    Prague, Czechia · Not yet recruiting

  • Hôpital Bicêtre-- Assistance Publique Hopitaux de Paris

    Paris, France · Not yet recruiting

  • Hôpitaux Universitaires de Strasbourg

    Strasbourg, France · Not yet recruiting

  • DRK Kliniken Berlin Westend

    Berlin, Germany · Not yet recruiting

  • University Hospital Carl Gustav Carus of Technical University Dresden

    Dresden, Germany · Not yet recruiting

  • Universitätsmedizin Greifswald

    Greifswald, Germany · Not yet recruiting

  • Gottsegen National Cardiovascular lnstitute

    Budapest, Hungary · Not yet recruiting

  • Medical University of Szeged

    Szeged, Hungary · Not yet recruiting

  • Sapienza University of Rome

    Rome, Italy · Recruiting

  • John Paul II Hospital Krakow

    Krakow, Poland · Not yet recruiting

  • Fryderyk Chopin Hospital in European Health Centre Otwock

    Otwock, Poland · Not yet recruiting

  • Centro Hospitalar Lisboa Norte - Santa Maria University Hospital

    Lisbon, Portugal · Not yet recruiting

  • Emergency Institute for Cardiovascular Diseases Prof. Dr. C.C.Iliescu

    Bucharest, Romania · Not yet recruiting

  • Emergency Clinical County Hospital of Targu Mures

    Târgu Mureş, Romania · Not yet recruiting

  • Hospital Clinic of Barcelona

    Barcelona, Spain · Not yet recruiting

  • Hospital Ramon y Cajal

    Madrid, Spain · Not yet recruiting

  • Hospital Maciel

    Montevideo, Uruguay · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.